73 related articles for article (PubMed ID: 21656908)
1. Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors.
Frant J; Veerendhar A; Chernilovsky T; Nedvetzki S; Vaksman O; Hoffman A; Breuer E; Reich R
ChemMedChem; 2011 Aug; 6(8):1471-7. PubMed ID: 21656908
[TBL] [Abstract][Full Text] [Related]
2. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.
Hoffman A; Qadri B; Frant J; Katz Y; Bhusare SR; Breuer E; Hadar R; Reich R
J Med Chem; 2008 Mar; 51(5):1406-14. PubMed ID: 18257543
[TBL] [Abstract][Full Text] [Related]
3. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo.
Reich R; Hoffman A; Suresh RR; Shai O; Frant J; Maresca A; Supuran CT; Breuer E
J Enzyme Inhib Med Chem; 2015; 30(5):767-72. PubMed ID: 25669348
[TBL] [Abstract][Full Text] [Related]
4. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
[TBL] [Abstract][Full Text] [Related]
5. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
Farkas E; Katz Y; Bhusare S; Reich R; Röschenthaler GV; Königsmann M; Breuer E
J Biol Inorg Chem; 2004 Apr; 9(3):307-15. PubMed ID: 14762707
[TBL] [Abstract][Full Text] [Related]
6. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Michaelides MR; Dellaria JF; Gong J; Holms JH; Bouska JJ; Stacey J; Wada CK; Heyman HR; Curtin ML; Guo Y; Goodfellow CL; Elmore IB; Albert DH; Magoc TJ; Marcotte PA; Morgan DW; Davidsen SK
Bioorg Med Chem Lett; 2001 Jun; 11(12):1553-6. PubMed ID: 11412979
[TBL] [Abstract][Full Text] [Related]
7. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.
Reich R; Hoffman A; Veerendhar A; Maresca A; Innocenti A; Supuran CT; Breuer E
J Med Chem; 2012 Sep; 55(17):7875-82. PubMed ID: 22894736
[TBL] [Abstract][Full Text] [Related]
8. Characterization of matrix metalloproteinase inhibitors: angiogenesis and tumor models.
Albert DH; Davidsen SK
Curr Protoc Pharmacol; 2001 Aug; Chapter 5():Unit5.23. PubMed ID: 21959760
[TBL] [Abstract][Full Text] [Related]
9. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice.
Naito Y; Takagi T; Kuroda M; Katada K; Ichikawa H; Kokura S; Yoshida N; Okanoue T; Yoshikawa T
Inflamm Res; 2004 Sep; 53(9):462-8. PubMed ID: 15550999
[TBL] [Abstract][Full Text] [Related]
10. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
[TBL] [Abstract][Full Text] [Related]
12. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
13. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
14. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Curtin ML; Florjancic AS; Heyman HR; Michaelides MR; Garland RB; Holms JH; Steinman DH; Dellaria JF; Gong J; Wada CK; Guo Y; Elmore IB; Tapang P; Albert DH; Magoc TJ; Marcotte PA; Bouska JJ; Goodfellow CL; Bauch JL; Marsh KC; Morgan DW; Davidsen SK
Bioorg Med Chem Lett; 2001 Jun; 11(12):1557-60. PubMed ID: 11412980
[TBL] [Abstract][Full Text] [Related]
16. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines.
Shiraga M; Yano S; Yamamoto A; Ogawa H; Goto H; Miki T; Miki K; Zhang H; Sone S
Cancer Res; 2002 Oct; 62(20):5967-73. PubMed ID: 12384564
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
18. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium.
Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K
J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705
[TBL] [Abstract][Full Text] [Related]
20. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
